Kwality Pharmaceuticals Ltd (KPL) Fair Value & Analysis

Healthcare · IN · Market cap ₹27.8B

A solid business, but screening 65% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (₹1,584). The favourable scenario is already priced in.
• Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (₹848.01 to ₹1,584) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹49.00 – ₹3,591 · fair‑value band ₹848.01 – ₹1,584 · the ₹3,453 price screens above the ₹1,211 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Kwality Pharmaceuticals Ltd (KPL) currently trades at ₹3,453, while our model-based Fair Value estimate is ₹1,211, implying the stock looks roughly 64.9% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Kwality Pharmaceuticals Ltd generated revenue of ₹5.0B at a net margin of 13.4%. Revenue grew 35.8% year over year. It earns a return on equity of 22.7%. Net debt stands at ₹1.3B. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹848.01 (bear case) to ₹1,584 (bull case); at ₹3,453, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 317% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -65%, KPL screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹1,211) versus Asset-Based (₹214.11). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures, buys, sells, and deals finished pharmaceutical formulations in India and internationally.

Full company description

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures, buys, sells, and deals finished pharmaceutical formulations in India and internationally. It offers its products in various dosage forms, including liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments/cream, external preparations, ORS, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized and covid products, syrups, daunorubicin, and other various categories, such as Beta Lactam, non-Beta Lactam, hormones, cytotoxic (oncology), and effervescent. The company also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Kwality Pharmaceuticals Ltd reported revenue of ₹5.0B in FY2025 versus ₹6.3B in FY2021, a compound −5.3%/yr. Reported net income was ₹673M in FY2025, compounding +26.6%/yr from FY2021.

KPL screens 65% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 633 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.